Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Infectious Diseases
2
Pipeline Programs
2
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
ISLPhase 2/35 trials
Active Trials
NCT07266831Recruiting570Est. Apr 2030
NCT06891066Active Not Recruiting150Est. Sep 2031
NCT06811246Completed20Est. Jul 2024
+2 more trials
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
VesatolimodPhase 11 trial
Active Trials
NCT05458102Terminated18Est. May 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.ISL
Merck & Co.ISL
Merck & Co.ISL
Merck & Co.ISL
Merck & Co.ISL
Gilead SciencesVesatolimod
Merck & Co.ISL
Merck & Co.ISL
Merck & Co.ISL

Clinical Trials (9)

Total enrollment: 1,621 patients across 9 trials

NCT07266831Merck & Co.ISL

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Start: Dec 2025Est. completion: Apr 2030570 patients
Phase 2/3Recruiting
NCT06891066Merck & Co.ISL

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Start: Apr 2025Est. completion: Sep 2031150 patients
Phase 2Active Not Recruiting
NCT05130086Merck & Co.ISL

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Start: Oct 2022Est. completion: Mar 20240
Phase 2Withdrawn
NCT06811246Merck & Co.ISL

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Start: Feb 2024Est. completion: Jul 202420 patients
Phase 1Completed
NCT06619678Merck & Co.ISL

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

Start: Jan 2024Est. completion: Jun 202436 patients
Phase 1Completed
NCT05458102Gilead SciencesVesatolimod

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Start: Aug 2022Est. completion: May 202318 patients
Phase 1Terminated
NCT04515641Merck & Co.ISL

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Start: Nov 2020Est. completion: Sep 202112 patients
Phase 1Completed
NCT04303156Merck & Co.ISL

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Start: Jun 2020Est. completion: Oct 202012 patients
Phase 1Completed
NCT01026779Merck & Co.ISL

Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island

Start: Jul 2009Est. completion: Nov 2019803 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
7h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
7h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
11h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
23h ago

General Worker

GSK
Pakistan - Sindh - Karachi
23h ago

Vaccine Business Manager (Jakarta)

GSK
Indonesia - DKI Jakarta
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,621 patients
2 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)